Literature DB >> 16437666

Bone disorders in experimentally induced liver disease in growing rats.

Viktória Ferencz1, Csaba Horváth, Béla Kári, János Gaál, Szilvia Mészáros, Zsuzsanna Wolf, Dalma Hegedus, Andrea Horváth, Anikó Folhoffer, Ferenc Szalay.   

Abstract

AIM: To investigate the change of bone parameters in a new model of experimentally induced liver cirrhosis and hepatocellular carcinoma (HCC) in growing rats.
METHODS: Fischer-344 rats (n = 55) were used. Carbon tetrachloride (CCl(4)), phenobarbital (PB), and a single diethylnitrosamine (DEN) injection were used. Animals were killed at wk 8 and 16. Bone mineral content, femoral length, cortical index (quotient of cortical thickness and whole diameter) and ultimate bending load (F(max)) of the femora were determined. The results in animals treated with DEN+PB+CCl(4) (DPC, n = 21) were compared to those in untreated animals (UNT, n = 14) and in control group treated only with DEN+PB (DP, n = 20).
RESULTS: Fatty liver and cirrhosis developed in each DPC-treated rat at wk 8 and HCC was presented at wk 16. No skeletal changes were found in this group at wk 8, but each parameter was lower (P<0.05 for each) at wk 16 in comparison to the control group. Neither fatty liver nor cirrhosis was observed in DP-treated animals at any time point. Femoral length and F(max) values were higher (P<0.05 for both) in DP-treated animals at wk 8 compared to the UNT controls. However, no difference was found at wk 16.
CONCLUSION: Experimental liver cirrhosis and HCC are accompanied with inhibited skeletal growth, reduced bone mass, and decreased mechanical resistance in growing rats. Our results are in concordance with the data of other studies using different animal models. A novel finding is the transiently accelerated skeletal growth and bone strength after a 8-wk long phenobarbital treatment following diethylnitrosamine injection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16437666      PMCID: PMC4725093          DOI: 10.3748/wjg.v11.i45.7169

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

1.  Bone changes and mineral metabolism disorders in rats with experimental liver cirrhosis.

Authors:  A Nakano; T Kanda; H Abe
Journal:  J Gastroenterol Hepatol       Date:  1996-12       Impact factor: 4.029

2.  Osteodystrophy in patients with chronic hepatitis and liver cirrhosis.

Authors:  K Tsuneoka; Y Tameda; K Takase; T Nakano
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

3.  Bone mineral density and bone structure parameters as predictors of bone strength: an analysis using computerized microtomography and gastrectomy-induced osteopenia in the rat.

Authors:  M Stenström; B Olander; D Lehto-Axtelius; J E Madsen; L Nordsletten; G A Carlsson
Journal:  J Biomech       Date:  2000-03       Impact factor: 2.712

4.  Effects of 1,25(OH)2D3 on turnover, mineralization, and strength of bone in growing rats with liver cirrhosis induced by administration of carbon tetrachloride.

Authors:  Shinya Tanaka; Hiroshi Tsurukami; Akinori Sakai; Nobukazu Okimoto; Satoshi Ikeda; Hajime Otomo; Toshitaka Nakamura
Journal:  Bone       Date:  2003-03       Impact factor: 4.398

5.  Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis: relation to liver and kidney function and bone metabolism.

Authors:  S Møller; M Hansen; J Hillingso; J E Jensen; J H Henriksen
Journal:  Gut       Date:  1999-03       Impact factor: 23.059

6.  The environmental pollutant 1,1-dichloro-2,2-bis (p-chlorophenyl)ethylene induces rat hepatic cytochrome P450 2B and 3A expression through the constitutive androstane receptor and pregnane X receptor.

Authors:  Michael E Wyde; Erika Bartolucci; Akiko Ueda; He Zhang; Binfang Yan; Masahiko Negishi; Li You
Journal:  Mol Pharmacol       Date:  2003-08       Impact factor: 4.436

7.  Transcriptional regulation of CYP2B1 induction in primary rat hepatocyte cultures: repression by epidermal growth factor is mediated via a distal enhancer region.

Authors:  Daniel Bauer; Nils Wolfram; Georg F Kahl; Karen I Hirsch-Ernst
Journal:  Mol Pharmacol       Date:  2004-01       Impact factor: 4.436

8.  Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.

Authors:  C H Janes; E R Dickson; R Okazaki; S Bonde; A F McDonagh; B L Riggs
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

9.  Decreased serum osteocalcin levels in patients with liver cirrhosis.

Authors:  P Pietschmann; H Resch; C Müller; W Woloszczuk; R Willvonseder
Journal:  Bone Miner       Date:  1990-02

10.  Low bone mineral density in noncholestatic liver cirrhosis: prevalence, severity and prediction.

Authors:  Fátima Aparecida Ferreira Figueiredo; Cynthia Brandão; Renata de Mello Perez; Walnei Fernandes Barbosa; Mario Kondo
Journal:  Arq Gastroenterol       Date:  2004-03-15
View more
  2 in total

1.  Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor.

Authors:  Tsutomu Fujii; Bryan C Fuchs; Suguru Yamada; Gregory Y Lauwers; Yakup Kulu; Jonathan M Goodwin; Michael Lanuti; Kenneth K Tanabe
Journal:  BMC Gastroenterol       Date:  2010-07-09       Impact factor: 3.067

2.  Hepatoprotective Effects of Silybum marianum (Silymarin) and Glycyrrhiza glabra (Glycyrrhizin) in Combination: A Possible Synergy.

Authors:  Mahmood Rasool; Javed Iqbal; Arif Malik; Hafiza Sobia Ramzan; Muhammad Saeed Qureshi; Muhammad Asif; Mahmood Husain Qazi; Mohammad Amjad Kamal; Adeel Gulzar Ahmed Chaudhary; Mohammed Hussain Al-Qahtani; Siew Hua Gan; Sajjad Karim
Journal:  Evid Based Complement Alternat Med       Date:  2014-03-25       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.